CTLA4 and hereditary clear cell renal cell carcinoma: Targeting CTLA-4 and PD-1/PD-L1 pathways via using anti-CTLA-4 and anti-PD-1/anti-PD-L1 has achieved more efficacies in regressing melanoma, as compared to other cancers such as renal cell carcinoma [154].